Research Interests Overview
Prostate Cancer Research
Full details on the Prostate Cancer Research activities including:
- The UKGPCS (UK Genetic Prostate Cancer Study). Cancer Research UK/British Prostate Group/British Association of Urological Surgeons’ Section of Oncology Studies and the International ACTANE and PRACTICAL Consortium Studies.
- Studies of Molecular Markers in Familial versus Sporadic Prostate Cancer Tumour.s
- Gene–Environment Interaction Studies in Prostate Cancer.
- IMPACT (Identification of Men with a genetic predisposition to Prostate Cancer: Targeted screening in BRCA1 and BRCA2 mutation carriers and controls).
- Breast Cancer and Ovarian Cancer Screening Studies in High-Risk Individuals.
- A UK Multicentre Study of MRI versus Mammography as a Screening Measure in Women at High Risk of Breast Cancer (MARIBS): The Interaction of Genetic Risk with Screening Parameters.
Cancer Predisposition Gene Carriers - Testing, Epidemiology and Psychosocial studies
Full details on the Cancer Predisposition Gene Carriers research activities including:
- Psychosocial Studies of Predictive Genetic Testing
- An Epidemiological Study of the Interaction of Lifestyle Factors and Germline Mutation in the BRCA1/2 Genes (the EMBRACE study)
- A Serial Collection of Biological Samples from Individuals with Germline Mutations in the BRCA1/2 Genes
A Prospective Observational Study of Outcome and Survival Endpoints in BRCA1/2 Gene Carriers who have Undergone Prophylactic Surgery (the PROSE Study)
- We are determining the incidence of cancer after prophylactic breast and ovarian surgery and its psychological implications.
The UK Genetic Prostate Cancer Study
The UK Genetic Prostate Cancer Study (UKGPCS) was first established in 1993 and is the largest prostate cancer study of its kind in the UK, involving nearly 170 hospitals, 417 Consultants and 324 research nurses.
The Oncogenetics Team
The Oncogenetics Team aims to translate laboratory findings in genetic predisposition to cancer, to the clinic. The focus is on predisposition to prostate cancer.